Ten years of highly active antiretroviral therapy for HIV infection

被引:67
|
作者
Chen, Luke F.
Hoy, Jennifer
Lewin, Sharon R. [1 ]
机构
[1] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia
[2] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia
[3] Alfred Hosp, Clin Res Unit, Melbourne, Vic, Australia
关键词
D O I
10.5694/j.1326-5377.2007.tb00839.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past 10 years, the management of HIV infection has been transformed by an increased number of effective antiretrovirals (ARVs), with more convenient dosing and improved tolerability. Optimal management of HIV infection includes at least three effective ARVs; from at least two different drug classes. Current strategies and drugs can effectively control HIV and significantly reduce morbidity and mortality. However, no cure is yet possible. Appropriate use of ARVs leads to suppression of virological replication (to below the limit of detection using commercial assays to measure HIV in plasma) and an increase in CD4(+) T cells with few adverse effects. Greater than 95% adherence to drug therapy is required for effective viral suppression and immunological improvement. Monotherapy, two-drug combinations, sequential ARVs, drug "cycling", and treatment interruptions are ineffective management strategies and lead to earlier disease progression and emergence of drug resistance. Drug-drug interactions are common and caution is required when prescribing ARVs that inhibit or induce the cytochrome P450 pathway.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 50 条
  • [1] Monitoring of highly active antiretroviral therapy in HIV infection
    Walker, A. Sarah
    Gibb, Diana M.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2011, 24 (01) : 27 - 33
  • [2] Highly active antiretroviral therapy for HIV infection: lessons for the future
    Burger, DM
    van der Ven, AJAM
    Koopmans, PP
    NETHERLANDS JOURNAL OF MEDICINE, 2004, 62 (11): : 407 - 408
  • [3] HIV infection, highly active antiretroviral therapy and the cardiovascular system
    Barbaro, G
    CARDIOVASCULAR RESEARCH, 2003, 60 (01) : 87 - 95
  • [4] Sarcoidosis and HIV infection: Influence of highly active antiretroviral therapy
    Blanche, P
    Passeron, A
    Gombert, B
    Ginsburg, C
    Salmon, D
    Sicard, D
    BRITISH JOURNAL OF DERMATOLOGY, 1999, 140 (06) : 1185 - 1185
  • [5] The neuropathology of HIV infection in the era of highly active antiretroviral therapy
    Vallat-Decouvelaere, AV
    Chrétien, F
    de la Grandmaison, GL
    Carlier, R
    Force, G
    Gray, F
    ANNALES DE PATHOLOGIE, 2003, 23 (05) : 408 - 423
  • [6] Bronchoscopy yield in HIV-positive patients, ten years on from the introduction of highly active antiretroviral therapy
    Hadley, E. M.
    HIV MEDICINE, 2009, 10 : 48 - 49
  • [7] Osteoarticular complications related to HIV infection and highly active antiretroviral therapy
    Lima, Ana Lucia Lei Munhoz
    Zumiotti, Arnaldo Valdir
    Camanho, Gilberto Luis
    Benegas, Eduardo
    dos Santos, Alexandre Leme Godoy
    D'Elia, Caio Oliveira
    Oliveira, Priscila Rosalba Domingos
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (04): : 426 - 429
  • [8] Starting highly active antiretroviral therapy for HIV infection: Is it WIHS to wait?
    Schooley, RT
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (04) : 305 - 306
  • [9] Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection
    Caso, JAA
    Mingo, CS
    Tena, JG
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (16): : 1239 - 1240
  • [10] Response to highly active antiretroviral therapy according to duration of HIV infection
    Pezzotti, P
    Pappagallo, M
    Phillips, PN
    Boros, S
    Valdarchi, C
    Sinicco, A
    Zaccarelli, M
    Rezza, G
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (05) : 473 - 479